Fate Therapeutics Joins Biopharma's IPO Runway

Hoping to follow in the footsteps of two other companies focused on stem cells  Verastem Inc. and Stemline Therapeutics Inc.  that successfully completed their initial public offerings (IPOs) in 2012 and 2013 respectively, San Diego-based Fate Therapeutics Inc. filed its S-1 with the SEC to raise up to $69 million in an IPO.